CO2017007663A2 - Derivados de 4h-pirrol[3,2-c]piridin-4-ona - Google Patents
Derivados de 4h-pirrol[3,2-c]piridin-4-onaInfo
- Publication number
- CO2017007663A2 CO2017007663A2 CONC2017/0007663A CO2017007663A CO2017007663A2 CO 2017007663 A2 CO2017007663 A2 CO 2017007663A2 CO 2017007663 A CO2017007663 A CO 2017007663A CO 2017007663 A2 CO2017007663 A2 CO 2017007663A2
- Authority
- CO
- Colombia
- Prior art keywords
- pyridin
- pyrrole
- derivatives
- drugs
- compounds
- Prior art date
Links
- VXIKDBJPBRMXBP-UHFFFAOYSA-N 3H-pyrrole Chemical class C1C=CN=C1 VXIKDBJPBRMXBP-UHFFFAOYSA-N 0.000 title 1
- GCNTZFIIOFTKIY-UHFFFAOYSA-N 4-hydroxypyridine Chemical compound OC1=CC=NC=C1 GCNTZFIIOFTKIY-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Compuestos de fórmula (I). procesos para su producción y su uso como fármacos.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15152944 | 2015-01-28 | ||
| EP15200407 | 2015-12-16 | ||
| PCT/EP2016/051432 WO2016120196A1 (en) | 2015-01-28 | 2016-01-25 | 4h-pyrrolo[3,2-c]pyridin-4-one derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2017007663A2 true CO2017007663A2 (es) | 2017-10-10 |
Family
ID=55236350
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2017/0007663A CO2017007663A2 (es) | 2015-01-28 | 2017-07-28 | Derivados de 4h-pirrol[3,2-c]piridin-4-ona |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US10428063B2 (es) |
| EP (1) | EP3250567B1 (es) |
| JP (1) | JP6704398B2 (es) |
| KR (1) | KR102544847B1 (es) |
| CN (1) | CN107406417B (es) |
| AU (1) | AU2016212230B2 (es) |
| BR (1) | BR112017016193B1 (es) |
| CA (1) | CA2974853C (es) |
| CL (1) | CL2017001930A1 (es) |
| CO (1) | CO2017007663A2 (es) |
| CR (1) | CR20170345A (es) |
| CU (1) | CU20170094A7 (es) |
| DO (1) | DOP2017000176A (es) |
| EA (1) | EA032530B1 (es) |
| EC (1) | ECSP17048527A (es) |
| IL (1) | IL253284B (es) |
| JO (1) | JO3706B1 (es) |
| MX (1) | MX380239B (es) |
| MY (1) | MY182181A (es) |
| NI (1) | NI201700096A (es) |
| PE (1) | PE20171240A1 (es) |
| PH (1) | PH12017501340A1 (es) |
| SG (1) | SG11201705908VA (es) |
| SV (1) | SV2017005487A (es) |
| TN (1) | TN2017000329A1 (es) |
| TW (1) | TWI699359B (es) |
| UA (1) | UA122221C2 (es) |
| UY (1) | UY36544A (es) |
| WO (1) | WO2016120196A1 (es) |
| ZA (1) | ZA201705802B (es) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3157914B1 (en) | 2014-06-17 | 2018-09-26 | Bayer Pharma Aktiengesellschaft | 3-amino-1,5,6,7-tetrahydro-4h-indol-4-ones |
| CN107922389A (zh) | 2015-06-17 | 2018-04-17 | 拜耳制药股份公司 | 3‑氨基‑1,5,6,7‑四氢‑4h‑吲哚‑4‑酮 |
| US10308629B2 (en) | 2015-08-05 | 2019-06-04 | Bayer Pharma Aktiengesellschaft | 1H-pyrrol-3-amines |
| CN114716381B (zh) | 2015-12-16 | 2025-03-11 | 洛克索肿瘤学股份有限公司 | 可用作激酶抑制剂的化合物 |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| WO2018122168A1 (en) | 2016-12-29 | 2018-07-05 | Bayer Pharma Aktiengesellschaft | Combinations of bub1 kinase and parp inhibitors |
| WO2018158175A1 (en) | 2017-02-28 | 2018-09-07 | Bayer Pharma Aktiengesellschaft | Combination of bub1 inhibitors |
| WO2018206547A1 (en) | 2017-05-12 | 2018-11-15 | Bayer Pharma Aktiengesellschaft | Combination of bub1 and atr inhibitors |
| WO2018215282A1 (en) | 2017-05-26 | 2018-11-29 | Bayer Pharma Aktiengesellschaft | Combination of bub1 and pi3k inhibitors |
| KR102440006B1 (ko) | 2017-08-23 | 2022-09-05 | 현대모비스 주식회사 | 차량용 브레이크의 캘리퍼 장치 |
| EP3700904B1 (en) | 2017-10-24 | 2023-07-19 | Bayer AG | 4h-pyrrolo[3,2-c]pyridin-4-one derivatives |
| WO2020092528A1 (en) | 2018-10-31 | 2020-05-07 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity |
| US11203591B2 (en) | 2018-10-31 | 2021-12-21 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds |
| EP3915985A4 (en) | 2019-01-18 | 2022-09-28 | Voronoi Co., Ltd. | PYRROLOPYRIDE DERIVATIVE AND USE THEREOF FOR THE PREVENTION AND TREATMENT OF PROTEIN KINASE RELATED DISEASES |
| EP3921317B1 (en) | 2019-02-07 | 2023-08-02 | Bayer Aktiengesellschaft | 3-amino-2-[2-(acylamino)pyridin-4-yl]-1,5,6,7-tetrahydro-4h-pyrrolo[3,2-c]pyridin-4-one as csnk1 inhibitors |
| US20240307362A1 (en) | 2019-04-24 | 2024-09-19 | Bayer Aktiengesellschaft | 4H-PYRROLO[3,2-c]PYRIDIN-4-ONE COMPOUNDS |
| DK3959211T3 (da) * | 2019-04-24 | 2026-04-27 | Bayer Ag | 4h-pyrrol[3,2-c]pyridin-4-on-forbindelser |
| US12403135B2 (en) * | 2019-04-24 | 2025-09-02 | Bayer Aktiengesellschaft | 4H-pyrrolo[3,2-c]pyridin-4-one derivatives |
| EP3972695A1 (en) | 2019-05-23 | 2022-03-30 | Gilead Sciences, Inc. | Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors |
| WO2022023340A1 (en) | 2020-07-29 | 2022-02-03 | Bayer Aktiengesellschaft | Substituted heterocyclic compounds and therapeutic uses thereof |
| US20230322767A1 (en) | 2020-07-29 | 2023-10-12 | Bayer Aktiengesellschaft | Aryl substituted pyrrolo-pyridinones and therapeutic uses thereof |
| US20230365554A1 (en) | 2020-07-29 | 2023-11-16 | The Broad Institute, Inc. | Substituted pyrrolo-pyridinone derivatives and therapeutic uses thereof |
| EP4188928B1 (en) | 2020-07-29 | 2024-07-24 | Bayer Aktiengesellschaft | Substituted 1 h-pyrrolo[3,2-b]pyridin compounds and methods of use thereof |
| CN115836070B (zh) * | 2020-08-10 | 2024-08-09 | 上海和誉生物医药科技有限公司 | 作为egfr抑制剂的稠环化合物及其制备方法和应用 |
| KR20230094197A (ko) | 2020-09-23 | 2023-06-27 | 스코르피온 테라퓨틱스, 인코퍼레이티드 | 암 치료에 유용한 피롤로[3,2-c]피리딘-4-온 유도체들 |
| CN116997549A (zh) * | 2020-09-23 | 2023-11-03 | 蝎子疗法股份有限公司 | 用于治疗癌症的吡咯并[3,2-c]吡啶-4-酮衍生物 |
| WO2022072645A2 (en) * | 2020-09-30 | 2022-04-07 | Scorpion Therapeutics, Inc. | Methods for treating cancer |
| KR20230107419A (ko) * | 2020-10-09 | 2023-07-14 | 스코르피온 테라퓨틱스, 인코퍼레이티드 | 암 치료 방법 |
| CN116981667A (zh) * | 2020-10-09 | 2023-10-31 | 蝎子疗法股份有限公司 | 用于癌症治疗的egfr和/或her2的杂环抑制剂 |
| WO2022094271A1 (en) * | 2020-10-30 | 2022-05-05 | Scorpion Therapeutics, Inc. | Methods for treating cancer |
| WO2022098992A1 (en) * | 2020-11-05 | 2022-05-12 | Scorpion Therapeutics, Inc. | Use of macrocyclic compounds in methods of treating cancer |
| KR20220081631A (ko) | 2020-12-09 | 2022-06-16 | 보로노이 주식회사 | 염증성 질환의 예방 및/또는 치료를 위한 피롤로-피리딘 유도체 화합물의 신규 용도 |
| EP4469457A4 (en) * | 2022-01-27 | 2026-01-21 | Broad Inst Inc | CSNK1 SUBSTITUTE HETEROCYCLIC INHIBITORS |
| CA3246654A1 (en) | 2022-03-24 | 2023-09-28 | Antares Therapeutics, Inc. | METHODS FOR SYNTHESIZING EGFR INHIBITORS |
| WO2024182715A1 (en) * | 2023-03-02 | 2024-09-06 | Schrödinger, Inc. | Heterocyclics as egfr inhibitors |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3966781A (en) | 1970-12-17 | 1976-06-29 | Merck Sharp & Dohme (I.A.) Corporation | Deuteration of functional group-containing hydrocarbons |
| US5011472A (en) | 1988-09-06 | 1991-04-30 | Brown University Research Foundation | Implantable delivery system for biological factors |
| AR056560A1 (es) | 2005-10-06 | 2007-10-10 | Astrazeneca Ab | Pirrolopiridinonas como moduladores cb1 |
| US20070142414A1 (en) | 2005-12-16 | 2007-06-21 | Pharmacia Italia S.P.A. | N-substituted pyrrolopyridinones active as kinase inhibitors |
| WO2009040399A1 (en) | 2007-09-28 | 2009-04-02 | Nerviano Medical Sciences S.R.L. | Substituted pyrrolo-pyrimidine derivatives, process for their preparation and their use as kinase inhibitors |
| DK2294065T3 (da) * | 2008-01-22 | 2014-04-28 | Vernalis R&D Ltd | Indolyl-pyridonderivater med checkpoint kinase 1 inhibitorisk aktivitet |
| US8546413B2 (en) * | 2009-06-15 | 2013-10-01 | Nerviano Medical Sciences S.R.L. | Substituted pyrimidinylpyrrolopyridinone derivatives, process for their preparation and their use as kinase inhibitors |
| US8791162B2 (en) | 2011-02-14 | 2014-07-29 | Merck Sharp & Dohme Corp. | Cathepsin cysteine protease inhibitors |
| UA111754C2 (uk) | 2011-10-06 | 2016-06-10 | Байєр Фарма Акцієнгезелльшафт | Заміщені бензиліндазоли для застосування як інгібіторів bub1-кінази для лікування гіперпроліферативних захворювань |
| JP6063945B2 (ja) * | 2011-10-07 | 2017-01-18 | ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ | キナーゼ阻害剤としての４−アルキル置換３，４−ジヒドロピロロ［１，２−ａ］ピラジン−１（２Ｈ）−オン誘導体 |
| CN103906732A (zh) | 2011-10-28 | 2014-07-02 | 株式会社钟根堂 | 用作hdac抑制剂的异羟肟酸酯衍生物以及包含所述衍生物的药物组合物 |
| ES2638144T3 (es) | 2011-12-21 | 2017-10-18 | Bayer Intellectual Property Gmbh | Bencilpirazoles sustituidos |
| ES2620316T3 (es) | 2012-05-11 | 2017-06-28 | Bayer Pharma Aktiengesellschaft | Cicloalquenopirazoles sustituidos como inhibidores de BUB1 para el tratamiento del cáncer |
| WO2014022752A1 (en) | 2012-08-03 | 2014-02-06 | Amgen Inc. | Macrocycles as pim inhibitors |
| ES2755772T3 (es) | 2012-11-07 | 2020-04-23 | Nerviano Medical Sciences Srl | Pirimidinil y piridinilpirrolopiridinonas sustituidas, proceso para su preparación y su uso como inhibidores de cinasas |
| WO2014147204A1 (en) | 2013-03-21 | 2014-09-25 | Bayer Pharma Aktiengesellschaft | Heteroaryl substituted indazoles |
| HK1218750A1 (zh) * | 2013-03-21 | 2017-03-10 | Bayer Pharma Aktiengesellschaft | 3-杂芳基取代的吲唑 |
| ES2652305T3 (es) | 2013-06-21 | 2018-02-01 | Bayer Pharma Aktiengesellschaft | Pirazoles heteroaril sustituidos |
| US9765058B2 (en) | 2013-06-21 | 2017-09-19 | Bayer Pharma Aktiengesellschaft | Substituted benzylpyrazoles |
| HK1222846A1 (zh) | 2013-06-21 | 2017-07-14 | Bayer Pharma Aktiengesellschaft | 取代的苄基吡唑 |
| HK1223097A1 (zh) | 2013-06-21 | 2017-07-21 | Bayer Pharma Aktiengesellschaft | 杂芳基取代的吡唑 |
| EP3033342A1 (en) | 2013-08-13 | 2016-06-22 | Grünenthal GmbH | Annelated pyrroles and their use as crac inhibitors |
| EP3157914B1 (en) * | 2014-06-17 | 2018-09-26 | Bayer Pharma Aktiengesellschaft | 3-amino-1,5,6,7-tetrahydro-4h-indol-4-ones |
| CN107922389A (zh) | 2015-06-17 | 2018-04-17 | 拜耳制药股份公司 | 3‑氨基‑1,5,6,7‑四氢‑4h‑吲哚‑4‑酮 |
| US10308629B2 (en) | 2015-08-05 | 2019-06-04 | Bayer Pharma Aktiengesellschaft | 1H-pyrrol-3-amines |
| US20200216439A1 (en) | 2015-12-16 | 2020-07-09 | Bayer Pharma Aktiengesellschaft | Hetero-1,5,6,7-tetrahydro-4h-indol-4-ones |
-
2016
- 2016-01-25 TN TNP/2017/000329A patent/TN2017000329A1/en unknown
- 2016-01-25 JP JP2017539454A patent/JP6704398B2/ja active Active
- 2016-01-25 CU CUP2017000094A patent/CU20170094A7/es unknown
- 2016-01-25 BR BR112017016193-1A patent/BR112017016193B1/pt active IP Right Grant
- 2016-01-25 UA UAA201708621A patent/UA122221C2/uk unknown
- 2016-01-25 KR KR1020177023372A patent/KR102544847B1/ko active Active
- 2016-01-25 SG SG11201705908VA patent/SG11201705908VA/en unknown
- 2016-01-25 EP EP16701600.5A patent/EP3250567B1/en active Active
- 2016-01-25 CR CR20170345A patent/CR20170345A/es unknown
- 2016-01-25 US US15/547,032 patent/US10428063B2/en active Active
- 2016-01-25 MY MYPI2017702724A patent/MY182181A/en unknown
- 2016-01-25 CN CN201680013096.2A patent/CN107406417B/zh active Active
- 2016-01-25 EA EA201791692A patent/EA032530B1/ru not_active IP Right Cessation
- 2016-01-25 WO PCT/EP2016/051432 patent/WO2016120196A1/en not_active Ceased
- 2016-01-25 AU AU2016212230A patent/AU2016212230B2/en active Active
- 2016-01-25 CA CA2974853A patent/CA2974853C/en active Active
- 2016-01-25 MX MX2017009831A patent/MX380239B/es unknown
- 2016-01-25 PE PE2017001288A patent/PE20171240A1/es unknown
- 2016-01-27 JO JOP/2016/0014A patent/JO3706B1/ar active
- 2016-01-28 TW TW105102745A patent/TWI699359B/zh active
- 2016-01-28 UY UY0001036544A patent/UY36544A/es not_active Application Discontinuation
-
2017
- 2017-07-03 IL IL253284A patent/IL253284B/en active IP Right Grant
- 2017-07-25 PH PH12017501340A patent/PH12017501340A1/en unknown
- 2017-07-27 EC ECIEPI201748527A patent/ECSP17048527A/es unknown
- 2017-07-28 CL CL2017001930A patent/CL2017001930A1/es unknown
- 2017-07-28 CO CONC2017/0007663A patent/CO2017007663A2/es unknown
- 2017-07-28 SV SV2017005487A patent/SV2017005487A/es unknown
- 2017-07-28 DO DO2017000176A patent/DOP2017000176A/es unknown
- 2017-07-28 NI NI201700096A patent/NI201700096A/es unknown
- 2017-08-25 ZA ZA2017/05802A patent/ZA201705802B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2017007663A2 (es) | Derivados de 4h-pirrol[3,2-c]piridin-4-ona | |
| UY36737A (es) | 3-amino-1,5,6,7-tetrahidro-4h-indol-4-onas | |
| CL2016002735A1 (es) | Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer | |
| ECSP18074962A (es) | Derivados de aminotiazol útiles como agentes antivíricos | |
| UY36175A (es) | 3-amino-1,5,6,7-tetrahidro-4h-indol-4-onas | |
| DOP2017000078A (es) | Indazoles sustituidos con bencilo como inhibidores de bub1. | |
| NI201600144A (es) | Derivados de quinoxalina utiles como moduladores del fgfr cinasa | |
| ECSP20021132A (es) | Enantiómeros de tiazoles sustituidos compuestos antivirales | |
| CL2016001895A1 (es) | Compuestos | |
| UY34657A (es) | ?derivados macrocíclicos para el tratamiento de enfermedades?. | |
| CO7210068A1 (es) | Nuevos derivados tienopirimidina, un proceso para su preparación y composiciones farmacéuticas que los contienen | |
| MX374558B (es) | Compuestos de heteroarilo y sus usos. | |
| MX2015012414A (es) | Sal de omecamtiv mecarbilo y proceso para preparar la sal. | |
| NI201500119A (es) | Compuestos de heteroarilo y sus usos | |
| UY35500A (es) | Indazoles sustituidos con heteroarilo | |
| UY34725A (es) | Nuevos derivados de tienopirimidina, procesos para su preparación y sus usos terapéuticos. | |
| DOP2018000083A (es) | NUEVOS DERIVADOS DE IMIDAZO[4,5-b]PIRIDINA, UN PROCESO PARA SU PREPARACIÓN Y COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN | |
| MX2016012784A (es) | Composiciones farmaceuticas solidas que comprenden derivados de biopterina y usos de tales composiciones. | |
| UY35997A (es) | Derivados de isoquinoleína, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| LT3230289T (lt) | 7-(morfolinil)-2-(n-piperazinil)metiltieno[2, 3-c]piridino dariniai kaip priešvėžiniai vaistai | |
| UY35610A (es) | Derivados de prodroga de triazolpiridinas sustituidas | |
| UY35665A (es) | ?compuestos de carboxamida, proceso de preparación y su uso como nematicidas?. | |
| MX373441B (es) | Derivados de indol-urea glucopiranosil-sustituido y su uso como inhibidores sglt. |